Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Kelly is an internationally recognized lung cancer expert dedicated to providing enhanced cancer care through cutting-edge clinical trials. Dr. Kelly’s lung cancer research spans the spectrum of the disease from prevention to treatment. She has been at the forefront of clinical trials development evaluating drugs to treat lung cancer and novel compounds to prevent lung cancer. She is also involved in developing biomarkers for screening and early detection of lung cancer. Dr.

Lung Cancer Video Library - Immunotherapy in Stage lll NSCLC - The Pacific Trial and Imfinzi
dbrock
Lung Cancer Video Library 2018
Author
Karen Kelly, MD, GRACE Faculty
Image

Dr. Karen Kelly, Associate Director for Clinical Research at UC Davis Comprehensive Cancer Center, met with GRACE to bring updates to our Lung Cancer Video Library.

In this video, Dr. Kelly discusses the role of immunotherapy in stage lll NSCLC, specifically the Pacific Trial and Imfinzi.


We thank the following organizations for their support  
Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

Here's the webinar on YouTube.  It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

Recent Comments

JOIN THE CONVERSATION
Webinar OnDemand
By JanineT GRACE … on
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on